These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19171609)

  • 1. Economic evaluation of tandem mass spectrometry newborn screening in Australia.
    Norman R; Haas M; Chaplin M; Joy P; Wilcken B
    Pediatrics; 2009 Feb; 123(2):451-7. PubMed ID: 19171609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of tandem mass spectrometry screening in California.
    Feuchtbaum L; Cunningham G
    Pediatrics; 2006 May; 117(5 Pt 2):S280-6. PubMed ID: 16735254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newborn screening with tandem mass spectrometry: examining its cost-effectiveness in the Wisconsin Newborn Screening Panel.
    Insinga RP; Laessig RH; Hoffman GL
    J Pediatr; 2002 Oct; 141(4):524-31. PubMed ID: 12378192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and cost-effectiveness of newborn screening for medium chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry.
    Tran K; Banerjee S; Li H; Noorani HZ; Mensinkai S; Dooley K
    Clin Biochem; 2007 Feb; 40(3-4):235-41. PubMed ID: 17222812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive cost-utility analysis of newborn screening strategies.
    Carroll AE; Downs SM
    Pediatrics; 2006 May; 117(5 Pt 2):S287-95. PubMed ID: 16735255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years.
    Wilcken B; Haas M; Joy P; Wiley V; Bowling F; Carpenter K; Christodoulou J; Cowley D; Ellaway C; Fletcher J; Kirk EP; Lewis B; McGill J; Peters H; Pitt J; Ranieri E; Yaplito-Lee J; Boneh A
    Pediatrics; 2009 Aug; 124(2):e241-8. PubMed ID: 19620191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of expanding newborn screening for up to 21 inherited metabolic disorders using tandem mass spectrometry: results from a decision-analytic model.
    Cipriano LE; Rupar CA; Zaric GS
    Value Health; 2007; 10(2):83-97. PubMed ID: 17391418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening newborns for inborn errors of metabolism by tandem mass spectrometry.
    Wilcken B; Wiley V; Hammond J; Carpenter K
    N Engl J Med; 2003 Jun; 348(23):2304-12. PubMed ID: 12788994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of neonatal ECG screening for the long QT syndrome.
    Quaglini S; Rognoni C; Spazzolini C; Priori SG; Mannarino S; Schwartz PJ
    Eur Heart J; 2006 Aug; 27(15):1824-32. PubMed ID: 16840497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Economic Evaluation of Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry in Thailand.
    Thiboonboon K; Leelahavarong P; Wattanasirichaigoon D; Vatanavicharn N; Wasant P; Shotelersuk V; Pangkanon S; Kuptanon C; Chaisomchit S; Teerawattananon Y
    PLoS One; 2015; 10(8):e0134782. PubMed ID: 26258410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal screening for inborn errors of metabolism: cost, yield and outcome.
    Pollitt RJ; Green A; McCabe CJ; Booth A; Cooper NJ; Leonard JV; Nicholl J; Nicholson P; Tunaley JR; Virdi NK
    Health Technol Assess; 1997; 1(7):i-iv, 1-202. PubMed ID: 9483160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Screening of newborns for inborn errors of metabolism by tandem mass spectrometry].
    Simonsen H
    Ugeskr Laeger; 2002 Nov; 164(48):5607-12. PubMed ID: 12523003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism.
    Geelhoed EA; Lewis B; Hounsome D; O'leary P
    J Paediatr Child Health; 2005 Nov; 41(11):575-9. PubMed ID: 16398841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential costs and benefits of newborn screening for severe combined immunodeficiency.
    McGhee SA; Stiehm ER; McCabe ER
    J Pediatr; 2005 Nov; 147(5):603-8. PubMed ID: 16291349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The failure to diagnose inborn errors of metabolism in New Zealand: the case for expanded newborn screening.
    Wilson C; Kerruish NJ; Wilcken B; Wiltshire E; Webster D
    N Z Med J; 2007 Sep; 120(1262):U2727. PubMed ID: 17891215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?
    Anderson R; Haas M; Shanahan M
    Aust N Z J Public Health; 2008 Feb; 32(1):43-52. PubMed ID: 18290913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of screening and correcting refractive errors in school children in Africa, Asia, America and Europe.
    Baltussen R; Naus J; Limburg H
    Health Policy; 2009 Feb; 89(2):201-15. PubMed ID: 18621429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a pilot study to evaluate tandem mass spectrometry for neonatal screening.
    Simonsen H; Jensen UG; Brandt NJ; Christensen E; Skovby F; Nørgaard-Pedersen B
    Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 2():166-9. PubMed ID: 11400760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of expanded newborn screening in Texas.
    Tiwana SK; Rascati KL; Park H
    Value Health; 2012; 15(5):613-21. PubMed ID: 22867769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. State newborn screening in the tandem mass spectrometry era: more tests, more false-positive results.
    Tarini BA; Christakis DA; Welch HG
    Pediatrics; 2006 Aug; 118(2):448-56. PubMed ID: 16882794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.